Table II.
Pharmacokinetic parameters for naltrexone (NTX) and its active metabolite, 6-β-naltrexol (NTXol) in human plasma.
NTX | NTXol | |||||
---|---|---|---|---|---|---|
Group 1 | Group 2 | Group 3 | Group 1 | Group 2 | Group 3 | |
Css, ng/ml | 1.2 (0.3) | 1.1 | NA | 2.0 (0.6) | NA | NA |
Tlag, h | 0.4 (0.8) | 0 | NA | 2.8 (1.4) | 48.0 | NA |
Cmax, ng/ml | 2.6 (0.7) | 2.77 | NA | 3.5 (1.3) | 0.49 | NA |
Tmax, h | 112.0 (62.7) | 8 | NA | 126.0 (41.3) | 48.0 | NA |
Clast, ng/ml | 1.4 (0.4) | 0 | NA | 1.89 (1.4) | 0 | NA |
AUC0–174 hr ng•h/ml | 196.5 (37.7) | 188.1 | NA | 335.8 (103.6) | 18.98 | NA |
Group 1 received treatment with MN + diclofenac + NTX gel (Group 3 received the same treatment but with no MN application), and Group 2 was treated with placebo gel.